


VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 28/02/2023) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of February, the sector traded on a forward EV / EBITDA multiple of 8.6x, compared to the ASX200 on 8.6x.



Average Values and Trading Multiples (values as at 28/02/2023) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$m)	EV/EBITDA FY2023	EV/EBIT FY2023	Price / Earnings FY2023
Aged Care	673	6.5x	11.4x	23.4x
Animal Health	161	6.2x	9.6x	12.2x
Biotech	128,641	18.7x	22.5x	33.3x
Hospitals & Clinics	45,013	9.3x	17.4x	21.3x
Medical Devices	1,226	NA	NA	N/A

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2021. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result. Composition of companies in Sector Dashboards are updated every 6 months. Most recent update: May 2021.

¹ The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.

MERGER & ACQUISITION NEWS...



Value: Not Disclosed

Vita Group has agreed to be wholly acquired by **Practice Management** by way of a court approved scheme of arrangement for a cash consideration of AUD 0.06255 per share, Vita Group said in a statement filed with the Australian Securities Exchange.



Value: Not Disclosed

Mercury Capital has acquired a stake in **Avive Health**, an Australia-based specialist mental health care provider, The Australian Financial Review reported on 14 March.



Value: Not Disclosed

Australian Clinical Labs Limited announces its intention to make an off-market takeover offer to acquire all of the fully paid ordinary shares (Healius Shares) on issue in **Healius Limited**. Strategic rationale is the expectation to bring significant benefits to both Healius and ACL shareholders and ACL believes that the two companies have the potential to be worth significantly more together than as standalone entities.



Value: Not Disclosed

AusCann Group Holdings Ltd has entered into a share sale agreement with **Animal Health Holdings Pty Ltd** to divest a 52% stake in its animal health business, **CannPal Animal Therapeutics Pty Ltd**, AusCann Group Holdings said in a statement filed with the Australian Securities Exchange. Rationale is that a privately held and focused animal health company is better positioned to attract, secure and maintain strategic partnerships and resources required for the continued development and commercialisation of AusCann's animal health assets.



UNDER THE MICROSCOPE...

- **Ochre Health**, an Australia-based rural medical practices business, is seeking buyers for a controlling stake in the company, The Australian Financial Review reported on 20 March. It is reported that Ochre has suspended earlier plans to list on the ASX and instead asked its adviser Highbury Partnership to find a buyer for the company.
- Private equity funds are believed to be circling **Integral Diagnostics**, an Australia-based diagnostic imaging business, The Australian reported on 13 March. Reported that private equity remains interested in healthcare targets, despite elevated funding costs.
- **BaptistCare**, an Australian aged care provider, is seeking acquisitions following the merger of BaptistCare NSW and ACT with BaptistCare in Western Australia, The Australian reported on 13 March. Aged care providers are facing increasing regulation and compliance need to invest increasingly large sums into technology systems and processes.
- **Healthia Ltd** will continue seeking acquisitions, given the fragmented nature of the targeted allied health industries, the Australia-based healthcare group said in an investor presentation material filed with the Australian Securities Exchange.
- **GenesisCare** lender **Blackstone** is believed to be leading a group of lenders pressuring the company to sell its Australian business, The Australian reported on 2 March. Reported that the Blackstone-led group is losing patience with GenesisCare and believes its best option is to sell its Australian business and use the profits to address challenges faced by its operations in the US.

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	0411 055 666	sdoyle@interfinancial.com.au
Brad Shaw	Chief Executive Officer	0499 058 582	bshaw@interfinancial.com.au
Mark Steinhardt	Director – M&A	0403 628 842	msteinhardt@interfinancial.com.au
David Hassum	Director	0411 132 251	dhassum@interfinancial.com.au
Andrew Wheeler	Director	0438 316 716	awheeler@interfinancial.com.au
Kalum De Silva	Director	0414 685 903	kdesilva@interfinancial.com.au
Graeme McKellar	Managing Director – IFL Ventures	0416 428 993	graeme@iflventures.com
Michael Kakanis	Associate Director	0421 212 534	mkakanis@interfinancial.com.au
Anuk Manchanda	Associate Director	0434 087 673	amanchanda@interfinancial.com.au
Nimerta Kumari	Associate Director	0459 165 035	nkumari@interfinancial.com.au
Jenny Zeng	Associate Director – IFL Ventures	0452 473 536	Jenny@iflventures.com
Lisa McKellar	Associate Director – IFL Ventures	0404 085 342	lisa@iflventures.com
Maggie Liu	Associate	0401 459 719	mliu@interfinancial.com.au
Nasia Christodoulou	Research Assistant	0427 737 493	nchristodoulou@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

InterFinancial
Corporate Finance Limited
ABN: 49 136 962 966
AFSL: 341675
Level 2, 201 Charlotte Street
GPO Box 975
Brisbane Queensland 4001
(07) 3218 9100
admin@interfinancial.com.au
www.interfinancial.com.au

